original ) (raw )Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
Neil Hawkins
Health Technology Assessment, 2006
View PDFchevron_right
Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis
Maiwenn Al
PloS one, 2018
View PDFchevron_right
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
Amanda Burls
Health technology assessment (Winchester, England), 2002
View PDFchevron_right
Exploratory analyses of clinical trial data used for health technology assessments: a retrospective evaluation
Ellen Snyder
BMJ Open
View PDFchevron_right
Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development
Bengt Jonsson
Molecular oncology, 2014
View PDFchevron_right
Future challenges for health economics and health technology assessment of biological drugs
László Gulácsi
The European Journal of Health Economics, 2010
View PDFchevron_right
Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European Access Academy
Ansgar Hebborn
Health Economics Review, 2022
View PDFchevron_right
Identification and assessment of ongoing trials in health technology assessment reviews
Yaser Adi
Health technology assessment (Winchester, England), 2004
View PDFchevron_right
Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense?
Alan Brennan
Rheumatology, 2004
View PDFchevron_right
West Midlands Health Technology Assessment Collaboration
Amanda Burls
View PDFchevron_right
Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development
Karl Claxton
2012
View PDFchevron_right
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
Ansgar Lange
The European journal of health economics : HEPAC : health economics in prevention and care, 2017
View PDFchevron_right
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
Hein Bernelot Moens , E. Brouwer
Arthritis Research & Therapy, 2015
View PDFchevron_right
Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence
Abdullah Pandor
nice.org.uk
View PDFchevron_right
EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment
Ingrid Klingmann
Frontiers in medicine, 2018
View PDFchevron_right
Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review
Matthew Sussman
Journal of Medical Economics
View PDFchevron_right
An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis: Focus on Tumour Necrosis Factor?? Antagonists
roberta ara
Drugs, 2005
View PDFchevron_right
Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
Alan Brennan
Rheumatology, 2007
View PDFchevron_right
The U.K. NHS ECONOMIC EVALUATION DATABASE Economic Issues in Evaluations of Health Technology
Julie Glanville
International Journal of Technology Assessment in Health Care, 2000
View PDFchevron_right
Cost-effectiveness of combination disease-modifying antirheumatics vs. tumour necrosis factor inhibitors in active rheumatoid arthritis: TACIT trial
Fowzia Ibrahim
Arthritis Care & Research
View PDFchevron_right
Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study
Sheila Hawker
Health Technology Assessment, 2008
View PDFchevron_right
Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis : scoping report
Philipp Egli
Bundesamt für Gesundheit, 2020
View PDFchevron_right
Modelling the cost effectiveness of TNF-α inhibitors in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
Alan Brennan
2006
View PDFchevron_right
Early economic evaluation of emerging health technologies: protocol of a systematic review
Mike Paulden
Systematic Reviews, 2014
View PDFchevron_right
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme research funding and UK burden of disease
Lisa Douet
Trials
View PDFchevron_right
The impact of the National Institute for Health Research Health Technology Assessment programme, 2003–13: a multimethod evaluation
Susan Guthrie
Health Technology Assessment, 2015
View PDFchevron_right
Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA):A decision analysis model
RITA JAIN
Seminars in Arthritis and Rheumatism, 1996
View PDFchevron_right
An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis
Alan Brennan
Drugs, 2005
View PDFchevron_right
A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions
Marta Soares
Value in Health, 2016
View PDFchevron_right
Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
Lourens T Bloem
Clinical Pharmacology & Therapeutics
View PDFchevron_right
Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review
Ron Akehurst
Current Rheumatology Reports, 2014
View PDFchevron_right
Bridging Trial and Decision: A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions
Manuela Joore
Value in Health, 2011
View PDFchevron_right
Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
Ron Akehurst
PharmacoEconomics, 2018
View PDFchevron_right